Join Oryzon Genomics for a virtual Key Opinion Leader (KOL) event exploring the significant unmet medical need and the evolving treatment landscape for Borderline Personality Disorder (BPD).

The event, moderated by Michael Ropacki, PhD and CMO for CNS at Oryzon, will feature insights from leading experts:

• Alan F. Schatzberg, MD, MS(Hon) – Stanford University School of Medicine
• Emil F. Coccaro, MD – The Ohio State University College of Medicine
• Eric Hollander, MD – Albert Einstein College of Medicine
• Sarah Fineberg, MD, PhD – Yale University School of Medicine

The event will provide an overview of the current social and clinical challenges for patients with Borderline Personality Disorder (BPD). It will highlight the absence of approved pharmacological treatments, the limitations of off-label medications, and the critical role of agitation and aggression in BPD and other psychiatric conditions. The discussion will also explore the potential of emerging therapies, with a focus on vafidemstat. The panel will also briefly review Oryzon’s recent interactions with the FDA and the design of vafidemstat’s PORTICO-2 Phase III trial protocol, which was recently submitted, and how vafidemstat ‘s novel epigenetic mechanism of action (MoA) may represent a promising treatment approach for BPD, schizophrenia, and autism spectrum disorder (ASD).

A live Q&A session will follow the panel discussion.